ALLR Allarity Therapeutics, Inc.
Financings ·
Allarity agreed to sell 1,562,500 shares at $1.60 each, or pre-funded warrants, to one investor, closing September 23, 2025. The investor may buy $7.5 million more: within 90 days per the 8-K, 60 days per the purchase agreement.
The buyer gets 1,562,500 shares or pre-funded warrants at $1.60 and can add $7.5 million more within 90 days, at a price set by Nasdaq's minimum-price rule.
Allarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier.
The company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review.
Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics for patients with high unmet medical need. It was founded on its Drug Response Predictor (DRP) platform, which defines gene expression signatures in cancer cells that predict sensitivity to a specific cancer therapeutic, so that patients likely to benefit can be identified from tumor biopsies. The company is now focused on stenoparib, a novel dual inhibitor of PARP1/2 and tankyrases, which it in-licensed with exclusive worldwide rights from Eisai Pharmaceuticals. Stenoparib has been explored in a Phase 2 clinical trial in patients with advanced, recurrent ovarian cancer who were pre-selected using the stenoparib DRP. A new clinical protocol was initiated in June 2025 and is enrolling patients randomized into two dose levels. The company is also developing the stenoparib DRP as a companion diagnostic to select patients for stenoparib treatment. Its other assets, including dovitinib, Irofulven and LiPlaCis, were terminated and are no longer part of its portfolio.
| Product or program | What it is | Stage |
|---|---|---|
| Stenoparib | Dual PARP1/2 and tankyrase inhibitor for advanced recurrent ovarian cancer | Phase 2 trial ongoing |
| Stenoparib DRP | Gene expression companion diagnostic to select patients for stenoparib | in development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $6.6 million | $6.1 million |
| Net income (loss) | -$11.2 million | -$24.5 million |
| Cash from operations | -$14.8 million | -$17.4 million |
| Cash and equivalents | $14.7 million | $19.5 million |
Our latest story on this, dated Sep 22, 2025: "Allarity Therapeutics agrees to $2.5 million private placement of shares and pre-funded warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2025: "Allarity Therapeutics delays quarterly report while auditors finish review". The story links the filing or release it is based on. Read the story.
Allarity Therapeutics, Inc. trades under the ticker ALLR on NASDAQ.
Allarity Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Allarity Therapeutics, Inc. is 1860657. Its filings are on SEC EDGAR.
15,910,724 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Allarity Therapeutics, Inc. under United States.
Our directory classifies Allarity Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Allarity Therapeutics, Inc. is US0167445008.
aibio.space lists Allarity Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company developing novel anti-cancer therapeutics for patients with high unmet medical need. It was founded on its Drug Response Predictor (DRP) platform, which defines gene expression signatures in cancer cells that predict sensitivity to a specific cancer therapeutic, so that patients likely to benefit can be identified from tumor biopsies.
Stenoparib: Dual PARP1/2 and tankyrase inhibitor for advanced recurrent ovarian cancer Stage: Phase 2 trial ongoing.
Stenoparib DRP: Gene expression companion diagnostic to select patients for stenoparib Stage: in development.
Allarity Therapeutics, Inc. reported a net loss of $11.2 million for the fiscal year ended Dec 31, 2025, and used $14.8 million of cash in operations, per its annual report to the SEC.
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio